The WHO says early results from Merck & Co’s Phase III Ebola vaccine trial show it is “highly effective” against Ebola and a “turning-point” in R&D.
Neupogen to bring in substantial future sales despite the arrival of Sandoz's biosimilar Zarxio in September, says Amgen.
Genomics services company Cellecta is offering gene-editing tool CRISPR to researchers wanting to “knock out” human gene functions.
Merck & Co. has strengthened its biologics pipeline through the acquisition of mAb developer cCAM and an extension of its nanobody deal with Ablynx.
Novartis has spun out three of its mid-to late-stage biologic candidates into a $119m (€108m) biotech.